Bacterial Diseases
5
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
7 treatments under study, led by Underglove Coating Skin Barrier
Research Leaders
5 sponsors active, led by National Institute Of Allergy And Infectious Diseases Niaid
Related Conditions
Often studied with 12 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
20%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (5)
Host Response to Infection by Direct Analysis of Leukocyte Single Cell-type Gene Expression/transcript Abundance, Direct LS-TA. a Prospective Study Will Evaluate the Performance of Direct LS-TA in Triage Febrile Patients Into Major Categories of Infections: Viral, Bacterial or Active Tuberculosis.
Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination
Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) Trial
Novel Protective Underglove
Reducing Vaginal Infections in Women
Research Network
Common Treatments
- Underglove Coating Skin Barrier1
- Triple Co Administration At Once Of The Combination Of Albendazole Ivermectin Azithromycin1
- No Intervention1
- Fluconazole1
- Metronizadole1
Active Sponsors
- National Institute Of Allergy And Infectious Diseases Niaid3
- University Of Washington1
- International Trachoma Initiative1
- Centre Dappui À La Lutte Contre La Maladie1
- Chinese University Of Hong Kong1
Related Conditions
- Active Tuberculosis1
- Gene Expression Profiling1
- Parasitic Diseases1
- Host Defense Mechanisms1
- Other Mycoses1